CCL launches new prostate cancer suite of tests to help patients and ease pressure on NHS

Cambridge Clinical Laboratories launches our new suite of tests to support the UK prostate cancer pathway.

Services, OncologyKelly Morel7 December 2021Cambridge Clinical LaboratoriesServices, Oncology, Prostate Cancer, Cancer

CCL partners with Prostatype Genomics to make Prostatype® prostate cancer test available for patients in UK & Ireland

Cambridge Clinical Laboratories (CCL) announces today, Friday 27 August, that CCL will be the UK partner for Prostatype Genomics in bringing the Prostatype® prostate cancer gene test to the UK market.

Services, OncologyKelly Morel27 August 2021Cambridge Clinical LaboratoriesServices, Oncology, Prostate Cancer, Cancer

Focus on: Prostate Cancer

A focus on Prostate Cancer - what it is, a snapshot of Prostate Cancer in the UK, and a summary of the tests available at Cambridge Clinical Laboratories.

OncologyKrishna Solanki28 June 2021Cambridge Clinical LaboratoriesProstate Cancer, Services

Prostate cancer diagnostic test (run through CCL) now available through BMI Healthcare

The Select MDx test that we run at Cambridge Clinical Laboratories is now available through BMI Healthcare. The test is a non-invasive urine test to improve patient selection for prostate cancer diagnostic biopsy and therefore will alleviate many from going through the invasive biopsy.

Company news, Press release, OncologyKelly Morel7 February 2020Cambridge Clinical LaboratoriesMDX, Prostate Cancer, BMI

News

Featured article